Patent · US Active

Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors

US11337973B2 · kind B2 · utility

0Cited by

1References

31Claims

0Family size

Assignees

BAYER HEALTHCARE LLC · DE
Bayer Pharma Aktiengesellschaft · DE

Inventors

Nicole BIBER · Wuppertal, DE
Damian Brockschnieder · Haan, DE
Florian Kölling · Wuppertal, DE
Jörg Meding · Wuppertal, DE
Hideki Miyatake Ondozabal · Berlin, DE
Thomas Neubauer · Wuppertal, DE
Martina Schäfer · Berlin, DE
Dmitry Zubov · Remscheid, DE
Carsten TERJUNG · Bochum, DE

Key dates

Filing date	Oct 31, 2018
Grant date	May 24, 2022
Priority date	—
Expiry date	Oct 31, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to prolyl endopeptidase (PREP) inhibitors of formula (I) which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.